Fast dissolving pharmaceutical compositions

1. An immediate release pharmaceutical composition in the form of a non-effervescent tablet, comprising:

(a) an amorphous solid dispersion comprising dasatinib in an amount of from about 17% w/w to about 21% w/w and copovidone in an amount of from about 38% w/w to about 42% w/w;

(b) mannitol in an amount of from about 11% w/w to 15% w/w;

(c) at least one gas generating agent comprising sodium bicarbonate in an amount of from about 10% w/w to about 14% w/w;

(d) crospovidone in an amount of from about 6% w/w to about 10% w/w;

(e) at least one acidic pH modifier comprising fumaric acid in an amount of from about 2% w/w to about 6% w/w;

(f) sodium stearyl fumarate in an amount of from about 0.1% w/w to about 4% w/w; and

(g) colloidal silicon dioxide in an amount of from about 0.1% w/w to about 1% w/w;

wherein the stated amounts are based on the total weight of the composition;

wherein the tablet optionally comprises a coating layer;

wherein the mole ratio of the at least one gas generating agent to the at least one acidic pH-modifier ranges from about 4:1 to about 1:4; and

wherein a dasatinib dose of 100 mg provides an AUC (0-24h) fed/AUC (0-24h) fasted ratio of from about 95% to about 100%, wherein AUC (0-24h) fed corresponds to the least-squares geometric mean of the AUC (0-24h) in fed patients and wherein AUC (0-24n) fasted corresponds to the least-squares geometric mean of the AUC (0-24h) in fasted patients.

2. The pharmaceutical composition of claim 1 , comprising

dasatinib in an amount of from 19% w/w to 20% w/w;

copovidone in an amount of from 39% w/w to about 40% w/w;

mannitol in an amount of from about 12% w/w to 14% w/w;

sodium bicarbonate in an amount of from 11% to 13% w/w;

crospovidone in an amount of from 8% w/w to 9% w/w;

fumaric acid in an amount of from 4% w/w to about 5% w/w;

sodium stearyl fumarate in an amount of from about 2% w/w to about 3% w/w; and

colloidal silicon dioxide in an amount of from about 0.4% w/w to about 0.6% w/w;

wherein the stated amounts are based on the total weight of the composition and wherein the tablet optionally comprises a coating layer.

3. The pharmaceutical composition of claim 1 , comprising

dasatinib in an amount of about 19% w/w;

copovidone in an amount of about 40% w/w;

mannitol in an amount of about 13% w/w;

sodium bicarbonate in an amount of about 12% w/w;

crospovidone in an amount of about 8% w/w;

fumaric acid in an amount of about 4.5% w/w;

sodium stearyl fumarate in an amount of about 2.5% w/w; and

colloidal silicon dioxide in an amount of about 0.5% w/w;

wherein the stated amounts are based on the total weight of the composition and wherein the tablet optionally comprises a coating layer.

4. A method of treating a disorder in a patient in need thereof, comprising administering a therapeutically effective amount of the composition of claim 1 to the patient, wherein said proliferative disorder is newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase;

adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

5. The method of claim 4 , wherein an amount of dasatinib in the pharmaceutical composition comprises 15 mg, 36 mg, 50 mg, 57 mg, 70 mg, or 100 mg.

6. The method of claim 4 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL, an AUC(0-∞) of about 877 ng⋅hr/mL, or a combination thereof.

7. The method of claim 4 , further comprising co-administering a gastric acid reducing agent comprising an antacid, an H2 antagonist, or a proton pump inhibitor.

8. The method of claim 7 , wherein the gastric acid reducing agent is administered shortly before the pharmaceutical composition is administered.

9. The method of claim 7 , wherein the gastric acid reducing agent is administered shortly after the pharmaceutical composition is administered.

10. The method of claim 7 , wherein the gastric acid reducing agent is administered concurrently with the pharmaceutical composition.

11. The method of claim 4 , wherein a dasatinib dose of X achieves bioequivalence to a dasatinib dose of Y for Sprycel, wherein X and Y are respectively selected from (i) 15 mg (X) and 20 mg (Y), (ii) 36 mg (X) and 50 mg (Y), (iii) 50 mg (X) and 70 mg (Y), (iv) 57 mg (X) and 80 mg (Y), (v) 70 mg (X) and 100 mg (Y), and (vi) 100 mg (X) and 140 mg (Y).

12. The method of claim 4 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL.

13. The method of claim 4 , wherein a dasatinib dose of 100 mg provides an AUC(0-∞) of about 877 ng⋅hr/mL.

14. The method of claim 4 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL and an intersubject coefficient of variation of about 12%.

15. The method of claim 4 , wherein a dasatinib dose of 100 mg provides a Cmax of about 241 ng/mL and an intrasubject coefficient of variation of about 29%.

16. The method of claim 4 , wherein a dasatinib dose of 100 mg provides an AUC(0-∞) of about 877 ng⋅h/mL and an intersubject coefficient of variation of about 9%.

17. The method of claim 4 , wherein a dasatinib dose of 100 mg provides an AUC(0-∞) of about 877 ngh/mL and an intrasubject coefficient of variation of about 14%.